Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-week dose-response study of mometasone furoate/formoterol and mometasone furoate in persistent allergic asthma
2007-001959-19Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mometasone and formoterol in allergic asthma and asthma (6 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline to Day 14 in exhaled nitric oxide. Started Feb 2008; status: completed.
02
Drugs
mometasoneformoterol
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2007-001959-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001959-19.